Shanghai, China

Wenbo Xiao


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):

Title: **Inventor Spotlight: Wenbo Xiao**

Introduction

Wenbo Xiao is a notable inventor based in Shanghai, China, recognized for his contributions to the field of pharmaceutical chemistry. His innovative work involves developing compounds that target specific cancer pathways, showcasing the intersection of science and impactful healthcare solutions.

Latest Patents

Wenbo Xiao holds a patent for a nitrogenous heterocyclic compound, detailing its preparation method, intermediate, composition, and applications. This patented compound exhibits high inhibitory activity against ErbB2 tyrosine kinase and demonstrates significant effectiveness against human breast cancer cells (BT-474) and gastric cancer cells (NCI-N87), which are known for high ErbB2 expression. Additionally, the compound functions as an EGFR/ErbB2 double target inhibitor, selectively modulating EGFR kinase activity and providing targeted treatment options for cancer therapy.

Career Highlights

Wenbo Xiao is currently associated with Shanghai Pharmaceuticals Holding Co., Ltd., where he contributes valuable expertise to ongoing research and development in pharmaceutical innovations. His role involves both inventive contributions and the strategic application of his findings to ensure effective medical treatments.

Collaborations

Throughout his career, Wenbo has collaborated with esteemed colleagues, including Guangxin Xia and Di Li, to advance their projects in pharmaceutical chemistry. These collaborations emphasize the importance of teamwork in achieving significant breakthroughs in drug development, combining diverse expertise to enhance overall research outcomes.

Conclusion

Wenbo Xiao is an exemplary figure in the realm of pharmaceutical innovation. His dedication to creating targeted cancer therapies through his patented compounds not only highlights his inventiveness but also reflects a broader commitment to improving healthcare solutions. As he continues to push the boundaries of pharmaceutical research, his work remains a vital asset to the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…